Array BioPharma

Array BioPharma is a clinical stage publicly traded pharmaceutical company (NASDAQ:ARRY)[1] that is in the NASDAQ Biotechnology Index and is worth over 990 million dollars.[2]

Pipeline

As of 2016, Array BioPharma has a number of compounds in clinical development.[3]

Drug Name Stage in Clinical Trials Development Partner Indication Target
Binimetinib (MEK162) Phase 3 None Cancer MEK
Encorafenib (LGX818) Phase 3 Pierre Fabre Cancer[4][5] BRAF
Selumetinib Phase 3 AstraZeneca Cancer MEK
Danoprevir Phase 3 Roche Hepatitis C NS3
Filanesib (ARRY-520) Phase 2 None Multiple myeloma[6] KSP
ARRY-797 Phase 2 None LMNA-related DCM p38
ARRY-502 Phase 2 None Asthma CRTh2
Ipatasertib (GDC-0068) Phase 2 Genentech Cancer AKT
Motolimod (VTX2337) Phase 2 VentiRX, Celgene Cancer TLR
Varlitinib (ASLAN001) Phase 2 ASLAN Cancer Pan-HER
LY2606368 Phase 2 Eli Lilly Cancer CHEK1
LOXO-101 Phase 2 Loxo Oncology Cancer Pan-TRK
ONT-380 Phase 2 Oncothyreon Breast cancer HER2/neu
ARRY-382 Phase 1 None Cancer CSF1R
ARRY-614 Phase 1 None Myelodysplastic syndrome (MDS) p38/Tie2
GDC-0575 Phase 1 Genentech Cancer CHEK1
GDC-0994 Phase 1 Genentech Cancer ERK

References

  1. ↑ "Array BioPharma Inc. (ARRY)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
  2. ↑ "^NBI Components NASDAQ Biotechnology Stock - Yahoo! Finance". finance.yahoo.com. Yahoo Finance. Retrieved 1 November 2016.
  3. ↑ "Product Pipeline".
  4. ↑ "Array, Pierre Fabre global commercialization agreement closes". www.denverpost.com. Denver Post.
  5. ↑ "Array BioPharma closes deal with French drug company". 9News. Tegna Corporation.
  6. ↑ Gitlin, Jonathan (2011). Multiple Myeloma: New Insights for the Healthcare Professional: 2011 Edition (2011 ed.). National Human Genome Research Institute. Retrieved 4 January 2016.


This article is issued from Wikipedia - version of the 11/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.